Australia's National Medicines Policy is outdated and in need of review

被引：5

作者：

Shaw, Brendan ^{[1
,2
]}

Chisholm, Orin ^{[1
]}

机构：

[1] Univ New South Wales, Sydney, NSW, Australia

[2] Shawview Consulting, London, England

来源：

MEDICAL JOURNAL OF AUSTRALIA | 2019年 / 211卷 / 06期

关键词：

Public health; Public policy; Health policy; Drug industry; Pharmaceuticals;

D O I：

10.5694/mja2.50268

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：252 / +

页数：4

共 13 条

[1]

Complementary Medicines Australia, 2018, AUSTR COMPL MED IND

[2]

Deloitte Center for Health Solutions , 2012, US HLTH CAR MARK STR

[3]

Department of Health and Ageing, 2018, EXP PRESCR 12 MONTHS

[4]

Department of Health and Ageing, 2003, AUSTR STAT MED 1999

[5]

Department of Health and Ageing, 1999, NAT MED POL 2000

[6]

Harvey K, 2001, AUSTR REV PUBLIC AFF

[7]

Hixon T, 2015, FORBES

[8] National medicines policies - a review of the evolution and development processes [J].

Hoebert J.M. ;

van Dijk L. ;

Mantel-Teeuwisse A.K. ;

Leufkens H.G.M. ;

Laing R.O. .

Journal of Pharmaceutical Policy and Practice, 6 (1)

[9] The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia [J].

Lichtenberg, Frank R. .

ECONOMIC RECORD, 2017, 93 (302) :353-378

[10]

Robertson J, 2012, ASIA PACIFIC C NAT S, V36, pS1

← 1 2 →